Last checked at 21 Jun 2021 13:35
Shield Therapeutics plc
("Shield Therapeutics" or the "Company")
Investor presentation
London, UK, 21 June 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that Greg Madison, Chief Executive Officer, will present at the OTCQX Life Science Virtual Investor Forum at 3.00pm BST (10am EST) on Thursday, 24 June 2021.
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. Investors can register to attend here: https://www.virtualinvestorconferences.com/events/event-details/life-sciences-investor-forum-1
No new material information will be disclosed at the event.
For further information, please contact:
Shield Therapeutics plc | +44 (0) 191 511 8500 | ||
Greg Madison (CEO) Hans-Peter Rudolf (CFO) | |||
Peel Hunt LLP - Nominated Adviser and Joint Broker | +44 (0) 20 7148 8900 | ||
James Steel / Christopher Golden | |||
finnCap Ltd - Joint Broker | +44 (0) 20 7220 0500 | ||
Geoff Nash / Alice Lane / Matthew Radley | |||
Walbrook PR - Financial PR & IR Adviser | +44 (0) 20 7933 8780 | ||
Paul McManus / Lianne Cawthorne | or shield@walbrookpr.com | ||
About Shield
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.
Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx